Oncimmune on track for a profit in 2025 as it continues to gain traction

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone takes Proactive's Stephen Gunnion through the company's 2024 trading update and its outlook for FY25. Gouldstone highlighted key achievements, including signing new contracts with top pharmaceutical companies and introducing innovative bioinformatics capabilities. These developments, coupled with the company's omics analysis contract, underscore Oncimmune's growing commercial traction. Gouldstone also confirmed that Oncimmune's revenues for last year totalled approximately £3 million. He expressed optimism about the year ahead, stating that the company expects to achieve profitability with anticipated revenues of £6.9 million, marking a significant milestone. Additionally, he discussed an exciting framework agreement with an R&D accelerator, which he sees as a strategic opportunity for growth in translational medicine. "With these new contracts landing right at the back end of our year, that sets us up rather well for this year," Gouldstone explained. Looking forward, these collaborations are expected to contribute to Oncimmune's revenue from the next calendar year onward. Visit Proactive’s YouTube channel for more exclusive interviews. Don’t forget to give this video a like, subscribe, and hit the notification bell for updates on future content. #OncimmuneHoldings #MartinGouldstone #Biopharma #OmicsAnalysis #Bioinformatics #AIinHealthcare #PharmaCollaborations #RevenueGrowth #TranslationalMedicine #Profitability #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews